Insulet Co. (NASDAQ:PODD) Shares Acquired by Private Advisor Group LLC

Private Advisor Group LLC lifted its position in shares of Insulet Co. (NASDAQ:PODDFree Report) by 131.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,387 shares of the medical instruments supplier’s stock after purchasing an additional 4,200 shares during the quarter. Private Advisor Group LLC’s holdings in Insulet were worth $1,719,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in PODD. Blue Trust Inc. grew its stake in shares of Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares during the period. International Assets Investment Management LLC acquired a new stake in Insulet in the 2nd quarter valued at $32,000. UMB Bank n.a. grew its stake in Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 81 shares during the period. CVA Family Office LLC grew its stake in Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 145 shares during the period. Finally, Massmutual Trust Co. FSB ADV grew its stake in Insulet by 159.2% in the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 254 shares of the medical instruments supplier’s stock valued at $51,000 after acquiring an additional 156 shares during the period.

Wall Street Analyst Weigh In

PODD has been the topic of a number of research analyst reports. Raymond James lifted their price target on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. UBS Group lifted their price target on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Piper Sandler lifted their price target on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Canaccord Genuity Group raised their price objective on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Finally, BTIG Research raised their price objective on Insulet from $250.00 to $260.00 and gave the company a “buy” rating in a report on Monday, October 14th. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $242.29.

Get Our Latest Stock Report on PODD

Insulet Stock Down 0.8 %

NASDAQ PODD opened at $230.58 on Thursday. Insulet Co. has a 52 week low of $128.68 and a 52 week high of $243.98. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. The business’s fifty day simple moving average is $225.17 and its 200-day simple moving average is $200.56. The firm has a market cap of $16.17 billion, a PE ratio of 41.92, a P/E/G ratio of 4.36 and a beta of 1.21.

Insulet (NASDAQ:PODDGet Free Report) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing the consensus estimate of $0.56 by ($0.01). The company had revenue of $488.50 million for the quarter, compared to analysts’ expectations of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. The firm’s revenue was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.38 EPS. As a group, equities analysts anticipate that Insulet Co. will post 3.04 earnings per share for the current year.

Insulet Company Profile

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

See Also

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.